On October 13, 2026 enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, reported that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Two community key opinion leaders (KOLs) from Colorado Urology, David J. Cahn, MD and Suzanne B. Merrill, MD, FACS, will review clinical case studies and discuss various real-world treatment considerations. To register, click here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Surfactants have been shown to boost efficacy with other NMIBC gene therapies in preclinical models and were subsequently incorporated into clinical development of those gene therapies. enGene is currently enrolling high-risk, BCG-unresponsive NMIBC patients with CIS in an additional cohort in its ongoing LEGEND trial, which incorporates a short surfactant bladder rinse (generic name: polidocanol) prior to intravesical administration of detalimogene. Detalimogene is an investigational, non-viral gene therapy for the treatment of high-risk, NMIBC.

A live question and answer session will follow the formal presentations.

About David J. Cahn, MD

Dr. Cahn is a board-certified urologist with fellowship training in neurourology. He brings years of extensive experience to complex urological conditions that require surgical intervention. Involved with InterStim technology since its approval by the Food and Drug Administration (FDA) in 1998, Dr. Cahn is one of Colorado’s most experienced minimally invasive surgeons treating overactive bladder. Dr. Cahn also specializes in advanced prostate cancer while still maintaining an active general urology practice. In addition, he serves as the Medical Director for Colorado Clinical Research, leading the practice’s clinical trials program.

Dr. Cahn has been in private practice since 1998 and founded Foothills Urology in 2000, now Colorado Urology. He is a member of the Colorado Urology Executive Council.

Dr. Cahn received his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and his bachelor’s degree at Wesleyan University. He completed his residency in urology at Montefiore Medical Center in the Bronx, New York, and his fellowship training in neurourology and female urology at the University of Colorado School of Medicine. He is board-certified by the American Board of Urology.

About Suzanne B. Merrill, MD, FACS

Dr. Suzanne B. Merrill is a board-certified urologist who is fellowship trained in Urologic Oncology. She specializes in the treatment of all cancers of the urinary tract, including bladder, upper tract/urothelial, kidney, prostate, testicular, adrenal, and penile cancer. Dr. Merrill utilizes robotic, minimally invasive as well as open surgical techniques to offer her patients with individualized and top-of-class treatment options. After a career in academic medicine, she transitioned to Colorado Urology where she became the bladder cancer and advanced therapeutic regional leader for the organization. In these roles, she ensures patients at Colorado Urology have access to the most cutting-edge bladder and kidney cancer FDA approved treatments as well as opportunities to engage in clinical trials that deliver highly anticipated novel therapies.

Dr. Merrill completed her bachelor’s degree with summa cum laude honors at The University of Delaware and obtained her Medical Doctorate at The University of North Carolina – Chapel Hill School of Medicine. She completed her residency at Duke University, followed by a Society of Urologic Oncology fellowship at The Mayo Clinic in Rochester, Minnesota. While at the Mayo Clinic, she also received a certificate in Translational Research. Prior to joining Colorado Urology, she was an Associate Professor of Urologic Oncology and Residency Program Director at Penn State Hershey Medical Center in Pennsylvania, where she was recognized with awards for her outstanding faculty leadership and mentorship, as well as humanism and professionalism in surgery.

(Press release, enGene Therapeutics, OCT 13, 2026, View Source [SID1234673367])

On October 13, 2026 Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, reported that an abstract submitted by its partner, VelaVigo, has been accepted for an oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Asia Congress 2026 taking place in Singapore from December 4–6, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VelaVigo will present preliminary safety, tolerability, and efficacy results from its ongoing Phase 1 study evaluating VBC103 (known as AVZO-103 outside of Mainland China, Hong Kong, Macau and Taiwan (collectively, "Greater China"), a bispecific Nectin-4/TROP2 antibody-drug conjugate ("ADC") that VelaVigo is developing in Greater China.

Details of the oral presentation are as follows:
Abstract: 2370
Title: First-in-human study of VBC103, a bispecific antibody-drug conjugate (ADC) targeting Nectin-4 and TROP2 as monotherapy in participants with advanced solid tumors
Speaker: Prof. Jian Zhang, Fudan University Shanghai Cancer Center
Session: Developmental therapeutics and precision medicine
Presentation Date and Time: Friday, December 4, 2026, 10:45–10:55 a.m. SGT
Location: Hall 402, Suntec Singapore Convention & Exhibition Centre

Avenzo is developing AVZO-103 outside of Greater China and is currently conducting a Phase 1/2 clinical study in patients with metastatic urothelial cancer or other solid tumors.

About AVZO-103

AVZO-103 (known as VBC103 in Greater China) is a potentially differentiated bispecific ADC designed to simultaneously target Nectin-4 and TROP2, two tumor antigens that are highly co-expressed across multiple solid tumors, including urothelial cancer. AVZO-103 is designed to address tumor heterogeneity and deliver a potent topoisomerase I inhibitor payload that may help overcome resistance to prior therapies. It is potentially a first-in-class molecule, being the first Nectin-4/TROP2 bispecific ADC to enter clinical development in the U.S. Avenzo is evaluating AVZO-103 in the BEACON-1 Phase 1/2 clinical study in patients with advanced solid tumors. The U.S. Food and Drug Administration has granted Fast Track designation to AVZO-103 for the treatment of adult patients with locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin. Avenzo holds exclusive global rights, excluding Greater China, from VelaVigo to develop, manufacture and commercialize AVZO-103.

(Press release, Avenzo Therapeutics, OCT 13, 2026, View Source [SID1234673366])

On October 13, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that Jose Conejo-Garcia, MD, PhD, inventor of Anixa’s CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference. The conference, hosted by Mayo Clinic and University of Minnesota, will be held November 2–3, 2026, in Rochester, Minnesota.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Conejo-Garcia’s presentation is titled "Closing in: Cracking Ovarian Cancer’s Resistance to Immunotherapy." He is Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine.

"Dr. Conejo-Garcia’s research into the immune biology of ovarian cancer led to the invention of the technology underlying lira-cel, our ovarian cancer CAR-T therapy," said Dr. Amit Kumar, Chairman and CEO of Anixa. "We are pleased that he will share his insights with the ovarian cancer research community at this conference."

Anixa’s ovarian cancer CAR-T therapy, liraltagene autoleucel, or lira-cel, is being evaluated in an ongoing Phase 1 clinical trial in collaboration with Moffitt Cancer Center. The investigational therapy uses chimeric endocrine receptor-T cell technology designed to target the follicle-stimulating hormone receptor, which is expressed on ovarian cancer cells but has limited expression in healthy tissues. The trial is designed to assess safety, tolerability, and preliminary signs of efficacy across escalating dose levels. To date, no dose-limiting toxicities have been observed, and four patients have surpassed one year of survival following treatment, with one of them having survived beyond two years. In addition, the first patient treated at the highest dose to date exhibited stable disease 90 days after treatment.

Presentation details:

Event: 2026 Ovarian Cancer Midwest Focus Conference
Speaker: Jose Conejo-Garcia, MD, PhD
Topic: Closing in: Cracking Ovarian Cancer’s Resistance to Immunotherapy
Location: Marriott Hotel, Rochester, Minnesota
Presentation date and time: 9:00 AM CT, Tuesday, November 3, 2026

The Ovarian Cancer Midwest Focus Conference brings together researchers, clinicians, patient advocates and others affected by ovarian cancer to share advances in research and care. Established at the University of Minnesota, the conference highlights work at Midwestern institutions and beyond, with a program spanning basic science, clinical research, emerging treatments and patient perspectives.

(Press release, Anixa Biosciences, OCT 13, 2026, View Source [SID1234673365])

On October 13, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) reported it will present results from multiple clinical studies at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress to be held in Madrid, Spain, from October 23 to 27, including data from its trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱) and another ADC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among them, multiple research findings for sac-TMT have been selected for oral presentations, including the Phase III OptiTROP-Lung04 and OptiTROP-Lung06 studies, which have both been selected for the "Non-Small Cell Lung Cancer (NSCLC), Metastatic" session and will be presented in the same time slot as proffered paper reports. In addition, data from the global pivotal Phase III TroFuse-005 trial led by MSD[1] will be presented for the first time in the ESMO (Free ESMO Whitepaper) Presidential Symposium.

The abstract titles of the above studies as well as other studies from Kelun-Biotech have been published on the official ESMO (Free ESMO Whitepaper) website. Details are as follows:

Lung cancer

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study

LBA66, Proffered paper | NSCLC, metastatic

October 25, 10:15 to 11:45 local time

Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study

LBA67, Proffered paper | NSCLC, metastatic

October 25, 10:15 to 11:45 local time

SKB500 (a novel B7-H3–targeted antibody-drug conjugate) in patients with extensive-stage small cell lung cancer (ES-SCLC): Results from a Phase I study

3816RO, Rapid oral | Non-metastatic NSCLC and other thoracic malignancies

October 26, 10:15 to 11:45 local time

Breast cancer

Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01

4639RO, Rapid oral | Breast cancer, advanced stage

October 26, 10:15 to 11:45 local time

Gynecologic cancers

Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study

LBA11, Proffered Paper | Presidential Symposium

October 26, 16:30 to 18:15 local time

Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC): Results from a Phase 2 study (2870-002/SKB264-II-06)

1259P, Poster | Gynaecological cancers

October 26, 12:00 to 12:45 local time

Genitourinary cancers

Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) for locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a Phase 2 Study (2870-002/SKB264-II-06)

4739RO, Rapid oral | Genitourinary tumours, renal and urothelial

October 24, 10:15 to 11:45 local time

About sac-TMT(佳泰莱)

Sac-TMT, a core product of the Company, is a novel TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload (KL610023) in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023 induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations by the NMPA.

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. Two new indication applications have been accepted for review by the NMPA: 1) sac-TMT in combination with pembrolizumab as first‑line treatment for locally advanced or metastatic NSCLC who have programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative; 2) sac‑TMT as first‑line treatment for patients with recurrent or metastatic TNBC who have a PD‑L1 combined positive score (CPS) <10 or have recurred after prior programmed cell death protein 1 (PD-1)/PD‑L1 inhibitor therapy in the early stage, both of the above two applications have been included in the priority review and approval process. As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 18 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About SKB500

SKB500 is a B7-H3-targeted ADC independently developed by the company using its OptiDCTM platform technology, featuring a site-specific cleavable linker and a potent topoisomerase I inhibitor. In the Phase I clinical study, SKB500 demonstrated robust efficacy and manageable safety profiles across multiple advanced solid tumors. Currently, two Phase II studies of SKB500 in extensive-stage small cell lung cancer (ES-SCLC) and advanced esophageal squamous cell carcinoma (ESCC),etc. are ongoing in China.

(Press release, Kelun, OCT 13, 2026, View Source [SID1234673364])

On October 13, 2026 Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, reported it will be presenting at the following upcoming scientific conferences:

2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress
October 25th, 2026 – Madrid, Spain

Title: HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1–high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)—phase 2 primary analysis
Format: Oral Presentation
Lead Author: Jong Chul Park
Date and Time: Sunday, October 25th, 2026; 8:30-10:00 AM CET

2026 Musculoskeletal Tumor Society (MSTS) Annual Meeting
October 29th, 2026 – Miami, Florida

Title: The Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Secondary Efficacy Endpoints from the Randomized, Registrational, Phase 2 ChonDRAgon study
Format: Oral Presentation
Lead Author: Robin Jones
Date and Time: Thursday, October 29th, 2026; 2:50-3:40 PM EST

2026 Connective Tissue Oncology Society (CTOS) Annual Meeting
November 19th – 20th, 2026 – Seoul, South Korea

Title: Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Subgroup Analysis and Updated Progression-Free Survival (PFS) from the Randomized, Phase 2 ChonDRAgon Study
Lead Author: Sant Chawla
Format: Oral Presentation
Date and Time: Friday, November 20th, 2026; 11:00 AM-12:30 PM KST

Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
Lead Author: Varun Monga
Format: Poster Presentation
Date and Time: Thursday, November 19th, 2026; 5:30-6:30 PM KST

The presentations and poster will be accessible through a link on the investors’ section of Inhibrx’s website at View Source, upon commencement of each event.

(Press release, Inhibrx, OCT 13, 2026, View Source [SID1234673363])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!